AlphAIalphai — Financial news for AI agents
simplywall.stAUG 212 min read$AUPH

Aurinia Pharmaceuticals (AUPH) After The Teva Settlement Is The Stock A Bargain

Aurinia Pharmaceuticals (AUPH) settled with Teva, delaying generic competition for voclosporin until 2036. AUPH shares rose 13.77% in 7 days, 12.51% YTD, closing at $17.27. Revenue is projected to grow 16-21% this year, with EPS potentially doubling. The stock is considered 17.8% undervalued with a fair value of $21.00, but faces risks like concentration around Lupkynis.

Original reporting
simplywall.st
Published Aug 21, 2026, 9:31 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 9:44 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Aurinia Pharmaceuticals (AUPH) After The Teva Settlement Is The Stock A Bargain — source image
Source · simplywall.st
Decision brief

The 30-second read

$AUPHBullishLow
01

Why it matters

Short‑term price rally reflects relief from generic threat, but long‑term valuation hinges on pipeline.

02

Market read

Article provides a brief post‑settlement price analysis with limited new information.

03

What to watch

Concentration risk on Lupkynis and uncertain pipeline beyond voclosporin.

Relevance 4/10Novelty 2/10Timing: post‑settlement price move

Background

Aurinia's Lupkynis is its sole commercial product; settlement delays generic competition.

Company-level read

Ticker impact

$AUPHBullishMedium confidence
Context

Article discusses Aurinia's recent settlement with Teva and the resulting 13.8% 7‑day price gain.

Expected impact

Potential further upside if settlement solidifies market share.

Evidence & confidence

Price already rallied on news; limited new catalyst beyond the settlement already priced.

Market effects

Sector

May boost confidence in lupus‑nephritis niche biotechs.

Regional

Limited to US biotech sector.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Settlement may signal future generic entry risk, limiting long‑term upside.

Key entities

  • company
    Aurinia Pharmaceuticals

    Biopharma with Lupkynis for lupus nephritis.

  • company
    Teva Pharmaceuticals

    Generic competitor involved in settlement.

Read at source← All news

Related articles

AUG 21
$MRNAHighAI 9/10

After Moderna’s Big News, Here Are Three Biotechs to Watch

Moderna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.

pro.thestreet.com3 min
AUG 20
$AUPHMed

Aurinia Pharmaceuticals (AUPH) Secures Patent Settlement With Teva, Blocking Lupkynis Generic Until 2036

Aurinia Pharmaceuticals (AUPH) settled a patent dispute with Teva (TEVA), delaying a generic version of Lupkynis until 2036. The deal boosted AUPH shares by 7%. Aurinia also settled with Sun Pharma in 2023 and faces ongoing litigation with other generics makers. Lupkynis is Aurinia's sole marketed drug, with H1 2026 revenue up 21% YoY to $161M, and full-year guidance of $315M-$325M.

londoninsider.co.uk2 min
AUG 20
$AUPHMed

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

Aurinia Pharmaceuticals settled patent litigation with Teva, pushing back potential generic competition for voclosporin until 2036. Aurinia's stock rose 6% on the news. Lupkynis, Aurinia's voclosporin product, recorded $153M in sales in H1 2026, up 21% YoY. Aurinia's patent litigation with other companies continues.

zacks.com2 min
AUG 19
$AUPHMed

Aurinia Settles Patent Litigation with Teva

Aurinia Pharmaceuticals (AUPH) settled patent litigation with Teva, which agreed to not launch its generic voclosporin product until December 7, 2036, unless certain conditions are met. Teva acknowledged the validity of Aurinia's patents, which expire in December 2037. Aurinia's litigation against other companies continues.

leaderpost.com2 min